CINQAIR

Опис товару

About CINQAIR

CINQAIR is a prescription medication containing the active ingredient reslizumab, a recombinant humanized monoclonal antibody. It is used to treat severe asthma in adults and children aged 12 years and older, characterized by an eosinophilic phenotype.

Key Benefits & Uses

• Treatment of severe asthma with an eosinophilic phenotype in adults and children aged 12 years and older.
• Reduction of oral corticosteroid use in patients with severe asthma.
• Improvement in asthma symptoms and lung function in patients with severe asthma.

Active Ingredient & Action

Reslizumab works by binding to the interleukin-5 (IL-5) protein, which is involved in the production and survival of eosinophils. By blocking IL-5, reslizumab reduces the number of eosinophils in the blood and airways, thereby reducing inflammation and improving asthma symptoms.

Important Notes

CINQAIR is administered via intravenous infusion every 4 weeks. It is essential to follow a strict dosing schedule and to have regular monitoring of eosinophil counts and asthma symptoms. Patients should also be aware of potential side effects, such as headache, fatigue, and nasopharyngitis. Consult a healthcare professional for more information and to discuss potential risks and benefits.